We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $2.98M → $0 (-$2.98M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
-$2.93M
2
IA
IFP Advisors
Florida
-$51.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
– -$2.93M -17,000 Closed
IA
2
IFP Advisors
Florida
– -$51.7K -300 Closed

RETA Hedge Fund Activity: Q4 2023 in Review

0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2023, worth a combined $0 — down 100% from $2.98M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RETA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $2.93M sold.

  • 0 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2023, down from 2 in Q3 2023.
  • Funds reported $0 of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2023 was DekaBank Deutsche Girozentrale, an estimated $2.93M sold.

Based on aggregated 13F filings for Q4 2023.